DelveInsight’s, “Varicella Zoster Infections Pipeline Insights, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Varicella Zoster Infections pipeline landscape.
Varicella Zoster Infections Pipeline landscape is provided which includes the disease overview and Varicella Zoster Infections treatment guidelines. The assessment part of the Varicella Zoster Infections pipeline report embraces, in depth Varicella Zoster Infections commercial assessment and clinical assessment of the pipeline products under development. In the Varicella Zoster Infections Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Varicella Zoster Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Varicella Zoster Infections Pipeline Report
Request a sample and discover the recent advances in Varicella Zoster Infections @ Varicella Zoster Infections Pipeline Outlook
Varicella Zoster Infections Overview
Varicella-zoster virus (VZV) is a pathogenic human alpha-herpesvirus that causes chickenpox (varicella) as a primary infection, which usually occurs in children in locales where vaccination is not practiced. Following the primary infection, this neurotropic virus becomes latent, primarily in neurons in peripheral autonomic ganglia throughout the entire neuroaxis including dorsal root ganglia (DRG), cranial nerve ganglia such as the trigeminal ganglia (TG), and autonomic ganglia including those in the enteric nervous system.
The diagnosis of VZV infection is usually made clinically by the appearance of the skin rash. In confusing or unusual appearing cases, the diagnosis may be made by identifying VZV DNA in skin lesions by PCR. Culture of VZV from skin lesions may also be used, but it is more expensive, takes more time, is poorly available, and is less sensitive than PCR.
Severe varicella may be prevented to some extent by administration of passive immunization with VariZig, a form of immunoglobulin containing high titers of antibodies to VZV; passive immunization should be administered as soon as possible after a recognised close exposure to VZV in a high-risk person who has never had varicella. Patients who develop zoster should be treated as soon as possible with acyclovir, famciclovir, or valacyclovir, which are administered orally. If zoster is severe, especially in immunocompromised patients, intravenous acyclovir can be administered, especially at the start of treatment surgery. Foscarnet is used to treat VZV infections that are resistant to ACV; the drug inhibits synthesis of VZV DNA polymerase.
Varicella Zoster Infections Pipeline Report
The Varicella Zoster Infections Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Varicella Zoster Infections, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Varicella Zoster Infections Pipeline Landscape.
Recent Developmental Activities in the Varicella Zoster Infections Pipeline Report
Varicella-zoster Infections Emerging Drugs
NBP608 is an immunostimulant which is being developed by SK Bioscience.
Varicella-zoster Infections Pipeline Therapeutic Assessment
Major Players in Varicella-zoster Infections There are approx. 3+ key companies which are developing the therapies for Varicella-zoster Infections. The companies which have their Varicella-zoster Infections drug candidates in the most advanced stage, i.e. phase III include, SK Bioscience.
Varicella-zoster Infections Pipeline Analysis Report
The Varicella-zoster Infections Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Scope of the Varicella-zoster Infections Pipeline Report
Dive deep into rich insights for Varicella-zoster Infections Pipeline Assessment, Visit @ Varicella-zoster Infections Pipeline Therapeutics Assessment
Table of Content
For further information on the Varicella-zoster Infections Pipeline therapeutics, reach out @ Varicella-zoster Infections Pipeline Landscape
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/